Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Kaysia Ludford"'
Autor:
Namrata Singh, Maria E Suarez-Almazor, Iman Osman, Jeffrey Weber, Adi Diab, Petros Grivas, Noha Abdel-Wahab, Ala Abudayyeh, Huifang Lu, Osama Rahma, Daniel H Johnson, Chrystia M Zobniw, Van A Trinh, Juhee Song, Jeffrey A Sparks, Sabina Sandigursky, Maya Dimitrova, May Daher, Maryam Buni, Kaysia Ludford, Faisal Fa'ak, Sarah H Chung, Uma Thanarajasingam, Adewunmi Falohun, Muhammad Osama Awiwi, Nourel Hoda Tahon, Khaled M Elsayes, Emma J Montazari, Julia Chernis, Osama Abu-Shawer, Ashley M Zeman, Rafee Talukder, Jean H Tayar
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 6 (2023)
Background Management of immune-related adverse events (irAEs) is important as they cause treatment interruption or discontinuation, more often seen with combination immune checkpoint inhibitor (ICI) therapy. Here, we retrospectively evaluated the sa
Externí odkaz:
https://doaj.org/article/a43e4d1fdb674d64bed3cf237bf2c36f
Autor:
Maro Ohanian, Farhad Ravandi, Maria E Suarez-Almazor, Noha Abdel-Wahab, Houssein Safa, Ala Abudayyeh, Stephen Gruschkus, May Daher, Richard Champlin, Kaysia Ludford, Guillermo Garcia-Manero, Hind Rafei, Jacinth Joseph, Gabriela Rondon, Laura Whited, Faisal Fa'ak, Cristina Knape, Mahran Shoukier, Megan Marcotulli, Alison M Gulbis, Betul Oran, Uday R Popat, Rotesh Mehta, Amin M Alousi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
Background Immune checkpoint inhibitors (ICIs) are being used after allogeneic hematopoietic stem cell transplantation (alloHCT) to reverse immune dysfunction. However, a major concern for the use of ICIs after alloHCT is the increased risk of graft-
Externí odkaz:
https://doaj.org/article/10e93fbbcd6b4e969d6a3f82162fa2d6
Autor:
Adi Diab, Faisal Fa’ak, Noha Abdel-Wahab, Jean Tayar, Huifang Lu, Maria Suarez-Almazor, Stephen Gruschkus, Daniel Johnson, Chantal Saberian, May Daher, Sang Kim, Maryam Buni, Kaysia Ludford
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/f6d37aa6536145f49bd865d8184367a7
Autor:
Kaysia Ludford, Won Jin Ho, Jane V. Thomas, Kanwal P.S. Raghav, Mariela Blum Murphy, Nicole D. Fleming, Michael S. Lee, Brandon G. Smaglo, Y. Nancy You, Matthew M. Tillman, Carlos Kamiya-Matsuoka, Selvi Thirumurthi, Craig Messick, Benny Johnson, Eduardo Vilar, Arvind Dasari, Sarah Shin, Alexei Hernandez, Xuan Yuan, Hongqui Yang, Wai Chin Foo, Wei Qiao, Dipen Maru, Scott Kopetz, Michael J. Overman
Publikováno v:
Journal of Clinical Oncology. 41:2181-2190
PURPOSE Pembrolizumab significantly improves clinical outcomes in advanced/metastatic microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) solid tumors but is not well studied in the neoadjuvant space. METHODS This is a phase II o
Autor:
Kaysia Ludford, Raphael Colle, Thierry André, Magali Svrcek, George J. Chang, Jane V Thomas, Michael J. Overman, Yann Parc, Romain Cohen, Van K. Morris, Wai Chin Foo, Scott Kopetz
Publikováno v:
J Natl Cancer Inst
Immune checkpoint inhibition (CPI) for metastatic colorectal cancer (mCRC) with deficient mismatch repair (dMMR) demonstrates high clinical activity that appears durable, but the impact of CPI on pathological tumor response is unknown. In this retros
Autor:
Deepak Bhamidipati, Kanwal Pratap Singh Raghav, Van K. Morris, Scott Kopetz, Bryan K. Kee, Benny Johnson, Jason Willis, Arvind Dasari, Maria Pia Morelli, Christine Megerdichian Parseghian, Michael Sangmin Lee, Phat Le, John Paul Y.C. Shen, Kaysia Ludford, Michael J. Overman
Publikováno v:
Journal of Clinical Oncology. 40:3524-3524
3524 Background: Markers of systemic inflammation including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (LMR) are prognostic in patients with metastatic colorectal cancer receiving system
Autor:
Kristen Simmons, Bryan K. Kee, Kanwal Pratap Singh Raghav, Benny Johnson, Scott Kopetz, Jason Willis, Arvind Dasari, Eduardo Vilar Sanchez, Kaysia Ludford, Christine Megerdichian Parseghian, Michael Sangmin Lee, Phat Le, John Paul Y.C. Shen, Michael J. Overman, Van K. Morris
Publikováno v:
Journal of Clinical Oncology. 40:3585-3585
3585 Background: Immune checkpoint blockade therapy improves survival in patients (pts) with microsatellite instability-high (MSI-H) advanced colorectal cancer (CRC). Oncologists often discontinue immunotherapy after 2 years of disease control based
Autor:
Noha Abdel-Wahab, Stephen K. Gruschkus, Maryam Buni, Daniel Johnson, Maria E. Suarez-Almazor, Jean Tayar, Adi Diab, Chantal Saberian, Sang Kim, May Daher, Faisal Fa’ak, Huifang Lu, Kaysia Ludford
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Management of certain immune mediated adverse events (irAEs) can be challenging and may require prolonged/chronic immune suppression with corticosteroids or other immunosuppressant which could compromise and even reverse the efficacy of im
Autor:
Chrystia M. Zobniw, May Daher, Muhammad Osama Awiwi, Adewunmi Falohun, Jean Tayar, Adi Diab, Noha Abdel-Wahab, Ashley M. Zeman, Ala Abudayyeh, Uma Thanarajasingam, Maryam Buni, VanAnh Trinh, Maria E. Suarez-Almazor, Daniel H. Johnson, Osama E. Rahma, Jeffrey A. Sparks, Linda Lu, Sabina Sandigursky, Jeffrey S. Weber, Osama Abu-Shawer, Amy Cunningham-Bussel, Kaysia Ludford, Namrata Singh, Khaled M. Elsayes, Rafee Talukder, Petros Grivas, Maya Dimitrova, Sarah H. Chung, Faisal Fa’ak
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A853-A853
BackgroundManaging immune-related adverse events (irAEs) has become a critical challenge with the increasing implementation of immune-checkpoint inhibitors (ICIs) in cancer treatment. IrAEs may cause treatment interruption or discontinuation, the rat
Autor:
Kanwal Pratap Singh Raghav, Jeffrey Thomas, Craig A. Messick, Wei Qiao, Michael J. Overman, Brandon G. Smaglo, Kaysia Ludford, Y.N. You, Scott Kopetz, M. S. Lee, Selvi Thirumurthi, Nicole D. Fleming, M.A. Blum Murphy, Eduardo Vilar, Douglas A. Nelson, Wai Chin Foo, Carlos Kamiya-Matsuoka, M.M. Tillman, Bruce E. Johnson
Publikováno v:
Annals of Oncology. 32:S1210